Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study by Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Arna H. Arnardottir, İlknur Dolu, Hans Hillege, Hans Hillege, Peter G. M. Mol, Peter G. M. Mol

Get full text

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model by Erik Bergman, Anna Maria Gerdina Pasmooij, Peter G. M. Mol, Gabriel Westman

Get full text

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe by Jeroen V. Koomen, Jeroen V. Koomen, Jasper Stevens, Margje H. Monster-Simons, Margje H. Monster-Simons, Hiddo J. L. Heerspink, Peter G. M. Mol, Peter G. M. Mol

Get full text

Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study by Hedvig Nordeng, Sonia Roldan Munoz, Angela Lupattelli, Sieta T de Vries, Peter G M Mol

Get full text

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting by Elisabeth Bakker, Peter G. M. Mol, Peter G. M. Mol, Peter G. M. Mol, João Nabais, João Nabais, Thorsten Vetter, Matthias Kretzler, John J. Nolan, Gert Mayer, Anna K. Sundgren, Hiddo J. L. Heerspink, Anja Schiel, Anja Schiel, Sieta T. de Vries, Maria F. Gomez, Friedrich Schulze, Dick de Zeeuw, Michelle J. Pena, for the BEAt-DKD Consortium

Get full text

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020 by Elisabeth Bakker, Viktoriia Starokozhko, Jet W. M. Kraaijvanger, Hiddo J. L. Heerspink, Peter G. M. Mol

Get full text

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment by Rianne A. Weersink, Rianne A. Weersink, Lotte Timmermans, Lotte Timmermans, Margje H. Monster-Simons, Margje H. Monster-Simons, Peter G. M. Mol, Peter G. M. Mol, Herold J. Metselaar, Sander D. Borgsteede, Sander D. Borgsteede, Katja Taxis

Get full text

Attention for sex in COVID-19 trials: a review of regulatory dossiers by Sieta T de Vries, Peter G M Mol, Harald Enzmann, Viktoriia Starokozhko, Ingrid M M Schellens, Leonoor Wijnans, Marco Cavaleri

Get full text

Adherence Barriers to Antimicrobial Treatment Guidelines in Teaching Hospital, the Netherlands by Peter G.M. Mol, Willem J.M.J. Rutten, Rijk O.B. Gans, John E. Degener, Flora M. Haaijer-Ruskamp

Get full text

Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency by Marieke J. H. J. Dekker, Sieta T. de Vries, Sieta T. de Vries, Carolien H. M. Versantvoort, Ellen G. E. Drost-van Velze, Mansi Bhatt, Peter J. K. van Meer, Ineke K. Havinga, Christine C. Gispen-de Wied, Peter G. M. Mol, Peter G. M. Mol

Get full text

Monoclonal antibody biosimilars for cancer treatment by Linda N. Broer, Daan G. Knapen, Derk-Jan A. de Groot, Peter G.M. Mol, Jos G.W. Kosterink, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge

Get full text

The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study by Fatma Karapinar-Çarkıt, Sander D. Borgsteede, Marjo J. A. Janssen, Marlies Mak, Nimet Yildirim, Carl E. H. Siegert, Peter G. M. Mol, Toine C. G. Egberts, Patricia M. L. A. van den Bemt

Get full text

Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. by Albert R Dreijer, Marieke J H A Kruip, Jeroen Diepstraten, Suzanne Polinder, Rolf Brouwer, Peter G M Mol, F Nanne Croles, Esther Kragten, Frank W G Leebeek, Patricia M L A van den Bemt

Get full text

Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy init... by Daphne H. Schoenmakers, Shanice Beerepoot, Sibren van den Berg, Laura Adang, Annette Bley, Jaap-Jan Boelens, Francesca Fumagalli, Wim G. Goettsch, Sabine Grønborg, Samuel Groeschel, Peter M. van Hasselt, Carla E. M. Hollak, Caroline Lindemans, Fanny Mochel, Peter G. M. Mol, Caroline Sevin, Ayelet Zerem, Ludger Schöls, Nicole I. Wolf

Get full text

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire by Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Elaine Julian

Get full text